Clinical Coagulation, Malmö
251 – 500 of 629
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Invasive Fusobacterium necrophorum infections and Lemièrre's syndrome: the role of thrombophilia and EBV.
(
- Contribution to journal › Article
-
Mark
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
(
- Contribution to journal › Article
-
Mark
Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden.
(
- Contribution to journal › Article
-
Mark
Inhibitors in haemophilia: what have we learned from registries? A systematic review.
(
- Contribution to journal › Scientific review
-
Mark
Genetic risk factors for inhibitors in haemophilia A
(
- Contribution to journal › Scientific review
-
Mark
Warfarin treatment complications do not correlate to cTTR when above 70.
(
- Contribution to journal › Article
-
Mark
Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
(
- Contribution to journal › Article
-
Mark
The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Prevention and treatment of atherosclerosis in haemophilia - how to balance risk of bleeding with risk of ischaemic events
(
- Contribution to journal › Scientific review
-
Mark
FVIII inhibitors: pathogenesis and avoidance.
(
- Contribution to journal › Scientific review
-
Mark
Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
(
- Contribution to journal › Article
-
Mark
Thrombin generation in two families with MYH9-related platelet disorder.
(
- Contribution to journal › Article
-
Mark
ABC om Yrsel på akuten
(
- Contribution to journal › Article
-
Mark
Buserelin treatment to rats causes enteric neurodegeneration with moderate effects on CRF-immunoreactive neurons and Enterobacteriaceae in colon, and in acetylcholine-mediated permeability in ileum.
(
- Contribution to journal › Article
- 2014
-
Mark
Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden.
(
- Contribution to journal › Article
-
Mark
Introduction.
(
- Contribution to journal › Article
-
Mark
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
(
- Contribution to journal › Article
-
Mark
Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.
(
- Contribution to journal › Scientific review
-
Mark
Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital
(
- Contribution to journal › Article
-
Mark
Thromboembolism, major bleeding and mortality in patients with mechanical heart valves- a population-based cohort study.
(
- Contribution to journal › Article
-
Mark
Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism.
(
- Contribution to journal › Article
-
Mark
Methods for individualising factor VIII dosing in prophylaxis
(
- Contribution to journal › Scientific review
-
Mark
Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism.
(
- Contribution to journal › Article
-
Mark
The association between red cell distribution width and venous thromboembolism: A biochemical evaluation
(
- Contribution to journal › Letter
-
Mark
Mechanical heart valve prosthesis and warfarin - Treatment quality and prognosis.
(
- Contribution to journal › Article
-
Mark
A longitudinal study of family structure in Swedish persons with haemophilia.
(
- Contribution to journal › Article
-
Mark
Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis.
(
- Contribution to journal › Article
-
Mark
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity
(
- Contribution to journal › Article
-
Mark
Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding.
(
- Contribution to journal › Scientific review
-
Mark
Risk and vulnerability of key populations to HIV infection in Iran; knowledge, attitude and practises of female sex workers, prison inmates and people who inject drugs
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?
(
- Contribution to journal › Article
-
Mark
The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Red cell distribution width and risk for venous thromboembolism: A population-based cohort study.
(
- Contribution to journal › Article
-
Mark
Atrial fibrillation patients do not benefit from acetylsalicylic acid
(
- Contribution to journal › Article
-
Mark
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
(
- Contribution to journal › Letter
-
Mark
Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B.
(
- Contribution to journal › Article
-
Mark
Managing Haemophilia for Life: 4th Haemophilia Global Summit
(
- Contribution to journal › Scientific review
-
Mark
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B - a systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
Inflammatory plasma markers and risk for venous thromboembolism.
(
- Contribution to journal › Article
-
Mark
Angiogenesis is increased in advanced haemophilic joint disease and characterized by normal pericyte coverage.
(
- Contribution to journal › Article
-
Mark
Outcome measures in haemophilia: a systematic review
(
- Contribution to journal › Scientific review
-
Mark
Textbook of hemophilia : Care of the child with hemophilia
2014) p.145-150(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Clinically relevant non-neutralizing anti-FVIII antibodies in a hemophiliac
(
- Contribution to journal › Letter
- 2013
-
Mark
Treatment with local hemostatic agents and primary closure after tooth extraction in warfarin treated patients.
(
- Contribution to journal › Article
-
Mark
HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey
(
- Contribution to journal › Article
-
Mark
Exploring Anti-FVIII Antibodies in Haemophilia A - Role in In Vitro Haemostasis and Clinical Disease
(
- Thesis › Doctoral thesis (compilation)
-
Mark
TEG och ROTEM--patientnära och snabba koagulationsanalyser. Minskar transfusionbehovet vid lever- och hjärtkirurgi, men frågetecken finns.
(
- Contribution to journal › Article
-
Mark
HIV prevalence and related risk behaviours among female sex workers in Iran: results of the national biobehavioural survey, 2010
(
- Contribution to journal › Article
-
Mark
Health-Related Quality of Life and Adherence in Haemophilia
(
- Thesis › Doctoral thesis (compilation)
-
Mark
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
(
- Contribution to journal › Article
-
Mark
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
(
- Contribution to journal › Article
-
Mark
APC resistance due to Factor V Leiden is not related to baseline inflammatory mediators or survival up to 10 years in patients with critical limb ischemia.
(
- Contribution to journal › Article
-
Mark
Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)
(
- Contribution to journal › Article
-
Mark
Somatosensory Sensitivity in Patients With Persistent Idiopathic Orofacial Pain Is Associated With Pain Relief From Hypnosis and Relaxation.
(
- Contribution to journal › Article
-
Mark
Increased burden on caregivers of having a child with haemophilia complicated by inhibitors.
2013) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
Thrombosis in patients with hemorrhagic disorders.
(
- Contribution to journal › Article
-
Mark
Platelet count kinetics following Interruption of antiretroviral treatment: Results from the SMART study.
(
- Contribution to journal › Article
-
Mark
Socioeconomic factors and concomitant diseases are related to the risk for venous thromboembolism during long time follow-up.
(
- Contribution to journal › Article
-
Mark
Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients: The GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
-
Mark
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
(
- Contribution to journal › Article
-
Mark
Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin.
(
- Contribution to journal › Article
-
Mark
Computer aided warfarin dosing in the Swedish national quality registry AuriculA - Algorithmic suggestions are performing better than manually changed doses
(
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
-
Mark
Dabigatran in clinical practice - One-year experience at Skåne University Hospital.
(
- Contribution to journal › Letter
-
Mark
Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article
-
Mark
Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
(
- Contribution to journal › Article
-
Mark
History of prophylaxis.
(
- Contribution to journal › Article
-
Mark
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.
(
- Contribution to journal › Article
- 2012
-
Mark
Arterial Thrombosis in Factor V Leiden or Activated Protein C Resistance. Clinical and Experimental Studies.
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Mortality and Inherited Thrombophilia: results from the European Prospective Cohort on Thrombophilia (EPCOT).
(
- Contribution to journal › Article
-
Mark
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
(
- Contribution to journal › Scientific review
-
Mark
Differences between developed and developing countries in paediatric care in haemophilia
(
- Contribution to journal › Article
-
Mark
Quality of life in adult patients with haemophilia - a single centre experience from Sweden.
(
- Contribution to journal › Article
-
Mark
Computerised assistance for warfarin dosage - Effects on treatment quality
(
- Contribution to journal › Article
-
Mark
Management of bleeding disorders in children
(
- Contribution to journal › Scientific review
-
Mark
Evaluation of recurrent venous thromboembolism in patients with Factor V Leiden mutation in heterozygous form.
(
- Contribution to journal › Article
-
Mark
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)
(
- Contribution to journal › Article
-
Mark
Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
(
- Contribution to journal › Letter
-
Mark
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
(
- Contribution to journal › Article
-
Mark
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry
(
- Contribution to journal › Article
-
Mark
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
(
- Contribution to journal › Article
-
Mark
The Arosenius Fund.
(
- Contribution to journal › Article
-
Mark
von Willebrand's disease: a report from a meeting in the Åland islands.
(
- Contribution to journal › Article
-
Mark
Models of prophylaxis.
(
- Contribution to journal › Article
-
Mark
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
(
- Contribution to journal › Article
-
Mark
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
(
- Contribution to journal › Article
-
Mark
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
(
- Contribution to journal › Article
-
Mark
Clinical trial design in haemophilia.
(
- Contribution to journal › Article
-
Mark
Malignant disease in the haemophilic population: moving towards a management consensus?
(
- Contribution to journal › Article
-
Mark
Modern haemophilia care.
(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey.
(
- Contribution to journal › Letter
-
Mark
Prevention and prediction of inhibitor risk.
(
- Contribution to journal › Article
-
Mark
Von Willebrand disease.
2012) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
2012) In Haemophilia(
- Contribution to journal › Article
-
Mark
New treatments in hemophilia: insights for the clinician.
(
- Contribution to journal › Article
- 2011
-
Mark
Risk factors for hemorrhage during local intra-arterial thrombolysis for lower limb ischaemia
(
- Contribution to journal › Article
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Bone Mineral Density in Haemophilila: A Treatment Outcome
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Article
-
Mark
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey
(
- Contribution to journal › Published meeting abstract
-
Mark
The pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions
(
- Contribution to journal › Article
-
Mark
Osteoporosis: a real problem in haemophilia?
(
- Contribution to journal › Published meeting abstract
-
Mark
Optimizing patient therapy - optimal dosing: when is enough enough?
(
- Contribution to journal › Article
-
Mark
Haematuria and hypertension in haemophilia - the H3 study
(
- Contribution to journal › Published meeting abstract
-
Mark
Bone density and health-related quality of life in adult patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
(
- Contribution to journal › Article
-
Mark
Thrombotic occlusion of all left coronary branches in a young woman with severe ulcerative colitis
2011) In ISRN Cardiology(
- Contribution to journal › Letter
-
Mark
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Recommendations for assessment, monitoring and follow-up of patients with haemophilia.
2011) In Haemophilia(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
-
Mark
Importance of rapid bleeding control in haemophilia complicated by inhibitors.
(
- Contribution to journal › Article
-
Mark
When von Willebrand disease comes into age - A matter of change?
(
- Contribution to journal › Article
-
Mark
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
The Swedish version of the Haemophilia Activity List.
(
- Contribution to journal › Article
-
Mark
Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
(
- Contribution to journal › Article
-
Mark
Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: A subgroup analysis from the AURICULA registry in Sweden.
(
- Contribution to journal › Article
-
Mark
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
(
- Contribution to journal › Article
-
Mark
Ovanliga ärftliga former av blödarsjuka. Blödningssymtom, familjehistoria och laboratorieanalyser ger diagnosen.
(
- Contribution to journal › Article
- 2010
-
Mark
Clinical probability assessment and biochemical markers in the diagnosis of deep vein thrombosis
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Treatment of Mesenteric Vein Thrombosis
(
- Contribution to journal › Article
-
Mark
Cellular Factor Xiii And Peptidylarginine Deiminase-Catalysed Citrullination In Rheumatoid Arthritis
2010) 30th European Workshop for Rheumatology Research In Annals of the Rheumatic Diseases 69(Suppl. 2).(
- Contribution to journal › Published meeting abstract
-
Mark
Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective
(
- Contribution to journal › Article
-
Mark
Von Willebrand disease prophylaxis network
(
- Contribution to journal › Published meeting abstract
-
Mark
Treatment of the critically ill patient with protein C: Is it worth the cost?
(
- Contribution to journal › Article
-
Mark
Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group
(
- Contribution to journal › Published meeting abstract
-
Mark
The role of prophylaxis in bleeding disorders
(
- Contribution to journal › Scientific review
-
Mark
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
(
- Contribution to journal › Article
-
Mark
The combination of Octaplex (R) and Octanate (R) restores thrombin generation capacity in FVIII inhibitor plasma in-vitro
(
- Contribution to journal › Published meeting abstract
-
Mark
The necessity of having FVIII in VWF concentrates
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.400-400(
- Contribution to journal › Published meeting abstract
-
Mark
The diagnostic performance of APC-PCI complex determination compared to d-dimer in the diagnosis of deep vein thrombosis
(
- Contribution to journal › Article
-
Mark
A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.31-31(
- Contribution to journal › Published meeting abstract
-
Mark
Clinical issues in inhibitors
(
- Contribution to journal › Scientific review
-
Mark
A retrospective study: of Octaplex (R) in the treatment of bleeding in patients with haemophilia A complicated by inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
Influence of the pre-analytical specimen storage conditions on thrombin generation assay
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.45-45(
- Contribution to journal › Published meeting abstract
-
Mark
Differential response to bypassing agents
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Network activities were initiated in December, 2009, and will extend over the next five years. von Willebrand disease prophylaxis network
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients Results From a Prospective Registry of European Hemophilia B Patients
(
- Contribution to journal › Published meeting abstract
-
Mark
F8 haplotype and recombinant product use in the Hemophilia Inhibitor Genetics Study (HIGS)
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylaxis in von Willebrand disease
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Assessment of health-related quality of life in patients with severe haemophilia with reduced bone density
(
- Contribution to journal › Published meeting abstract
-
Mark
Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study
(
- Contribution to journal › Published meeting abstract
-
Mark
Mild haemophilia in Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
(
- Contribution to journal › Article
-
Mark
A Cost-effectiveness Analysis of Diagnostic Algorithms of Deep Vein Thrombosis at the Emergency Department.
(
- Contribution to journal › Article
-
Mark
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
(
- Contribution to journal › Article
-
Mark
Upper extremity deep venous thrombosis in the population-based Malmö thrombophilia study (MATS). Epidemiology, risk factors, recurrence risk, and mortality.
(
- Contribution to journal › Article
-
Mark
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
(
- Contribution to journal › Article
-
Mark
Knowledge of disease and adherence in adult patients with haemophilia.
(
- Contribution to journal › Article
-
Mark
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
(
- Contribution to journal › Article
-
Mark
Anti-prothrombin antibodies are associated with thrombosis in children.
(
- Contribution to journal › Article
-
Mark
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
(
- Contribution to journal › Article
-
Mark
The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour.
(
- Contribution to journal › Article
- 2009
-
Mark
Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
(
- Contribution to journal › Article
-
Mark
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
2009) 10th International Symposium on Myelodysplastic Syndromes In Leukemia Research 33(Suppl 1). p.49-50(
- Contribution to journal › Published meeting abstract
-
Mark
Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.
(
- Contribution to journal › Published meeting abstract
-
Mark
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
(
- Contribution to journal › Article
-
Mark
Prospective analysis of risk factors and distribution of venous thromboembolism in the population-based Malmö Thrombophilia Study (MATS).
(
- Contribution to journal › Article
-
Mark
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
(
- Contribution to journal › Article
-
Mark
Physical activity as prevention of osteoporosis in patients with severe haemophilia on long term prophylaxis
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0118-0118(
- Contribution to journal › Published meeting abstract
-
Mark
Thrombin generation after emergency contraception
2009) 3rd International Symposium on Womens Health Issues in Thrombosis and Haemostasis In Thrombosis Research 123. p.152-152(
- Contribution to journal › Published meeting abstract
-
Mark
Increased thrombin generation in women with a history of preeclampsia
(
- Contribution to journal › Article
-
Mark
Haemate P/Humate-P: a systematic review.
(
- Contribution to journal › Article
-
Mark
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
(
- Contribution to journal › Article
-
Mark
Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin.
(
- Contribution to journal › Article
-
Mark
Lower incidence of procoagulant abnormalities during follow-up after creation of the Fontan circulation in children.
(
- Contribution to journal › Article
-
Mark
Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis.
(
- Contribution to journal › Article
-
Mark
Three-Year Survival and Stroke Recurrence Rates in Patients With Primary Intracerebral Hemorrhage.
(
- Contribution to journal › Article
-
Mark
Trombocytopeni kan vara HIT. Heparinbehandling kan ge livshotande låga trombocytvärden
(
- Contribution to journal › Article
- 2008
-
Mark
Asn1421Lys mutation in the glycoprotein Ib binding domain impairs - ristocetin and botrocetin - mediated binding of von Willebrand factor to platelets
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.116-116(
- Contribution to journal › Published meeting abstract
-
Mark
Genetic characterization of families with von Willebrand disease
(
- Thesis › Doctoral thesis (compilation)
-
Mark
VWD type 3 - historical review and contemporary treatment dilemmas
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Bone density in hemophilia
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.79-79(
- Contribution to journal › Published meeting abstract
-
Mark
The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.58-58(
- Contribution to journal › Published meeting abstract
-
Mark
von Willebrand disease update: diagnostic and treatment dilemmas
(
- Contribution to journal › Article
-
Mark
Genetic aspects and research development in haemostasis
(
- Contribution to journal › Article
-
Mark
Different approaches to primary prophylaxis in boys with severe hemophilia A
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.142-142(
- Contribution to journal › Published meeting abstract
-
Mark
Patients' and their family members' understanding of the genetics of type 1 von Willebrand disease.
(
- Contribution to journal › Letter
-
Mark
Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans.
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful tool in the management of haemophilia A patients?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.26-26(
- Contribution to journal › Published meeting abstract
-
Mark
Genetic aspects of inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.21-21(
- Contribution to journal › Published meeting abstract
-
Mark
European principles of haemophilia care
(
- Contribution to journal › Article
-
Mark
From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors
(
- Contribution to journal › Scientific review
-
Mark
The Swedish version of hemophilia activity list, HAL
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.74-74(
- Contribution to journal › Published meeting abstract
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
Surgical evaluation of a recombinant factorVIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients
(
- Contribution to journal › Article
-
Mark
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
(
- Contribution to journal › Scientific review
-
Mark
Transglutaminase and peptidylarginine deiminase in the pathogenesis of autoimmune diseases
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Variability of clinical manifestations of factor VII-deficiency in subjects homozygous or heterozygous for the F7 gene mutation A294V
(
- Contribution to journal › Letter
-
Mark
Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis
(
- Contribution to journal › Article
-
Mark
High purity, double virus-inactivated VWF/FVIII concentrate in long term prophylaxis of von Willebrand disease - experience from prospective clinical trials and German post-licensure surveillance
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.12-12(
- Contribution to journal › Published meeting abstract
-
Mark
New risk factors for inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.43-43(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylaxis in von Willebrand disease.
(
- Contribution to journal › Article
-
Mark
N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
(
- Contribution to journal › Article
-
Mark
Epidemiology, risk and prognostic factors in mesenteric venous thrombosis.
(
- Contribution to journal › Article
-
Mark
Protecting the joints of mice and men.
(
- Contribution to journal › Article
-
Mark
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
(
- Contribution to journal › Article
-
Mark
Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease.
(
- Contribution to journal › Article
-
Mark
Standardization and clinical utility of thrombin-generation assays.
(
- Contribution to journal › Article
-
Mark
The Factor V Leiden mutation is associated with a higher blood haemoglobin concentration in women below 50 of the Malmö Thrombophilia Study (MATS).
(
- Contribution to journal › Article
-
Mark
Oestrogen treatment of constitutional tall stature in girls: is there a risk of thrombosis or bleeding?
(
- Contribution to journal › Article
-
Mark
Patients’ and their family members’ understanding of the genetics of type 1 von Willebrand disease
2008)(
- Working paper/Preprint › Working paper
-
Mark
Arterial Thrombosis in mice with factor V Leiden mutation
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Blödningstidsbestämning har spelat ut sin roll. Otillförlitlig metod som inte längre bör användas i rutinsjukvården
(
- Contribution to journal › Scientific review
- 2007
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
(
- Contribution to journal › Article
-
Mark
Von Willebrand: The scientist, the disease, the factor, and the treatment
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Delays in maturation among adolescents with hemophilia and a history of inhibitors
(
- Contribution to journal › Article
-
Mark
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin (R)): a prospective study of 50 patients
(
- Contribution to journal › Article
-
Mark
In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
(
- Contribution to journal › Article
-
Mark
Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
(
- Contribution to journal › Article
-
Mark
Erik von Willebrand.
(
- Contribution to journal › Article
-
Mark
The APC-PCI complex concentration predicts outcome of aortic surgery.
(
- Contribution to journal › Article
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
Menorrhagia and minor bleeding symptoms in women on oral anticoagulation.
(
- Contribution to journal › Article
-
Mark
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor.
(
- Contribution to journal › Article
-
Mark
Evidens för trombosprofylax till medicinpatienter med hög risk
(
- Contribution to journal › Article
-
Mark
Gadolinium Contrast Agent is of Limited Value for Magnetic Resonance Imaging Assessment of Synovial Hypertrophy in Hemophiliacs.
(
- Contribution to journal › Article
-
Mark
VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
(
- Contribution to journal › Article
-
Mark
Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate((R)) P/Humate-P((R))) in von Willebrand Disease and Haemophilia A: A Viewpoint by Eric Berntorp.
(
- Contribution to journal › Letter
- 2006
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The need for prophylaxis in von Willebrand's disease and other coagulation disorders
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The von Willebrand Disease Prophylaxis Network (vWD PN): Exploring a treatment concept.
(
- Contribution to journal › Article
-
Mark
The complex between activated protein C and protein C inhibitor: A clinically useful indicator of aortic aneurysms?
(
- Contribution to journal › Article
-
Mark
The von Willebrand disease prophylaxis network: exploring a treatment concept.
(
- Contribution to journal › Article
-
Mark
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
(
- Contribution to journal › Article
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
(
- Contribution to journal › Article
-
Mark
Pharmacoeconomics of factor dosing in the haemophilia population.
(
- Contribution to journal › Article
-
Mark
Von Willebrand's disease: clinical management
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
(
- Contribution to journal › Article
-
Mark
Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia
(
- Contribution to journal › Article
-
Mark
New Approaches to Using FEIBA in the Treatment of Inhibitor Patients.
(
- Contribution to journal › Article
-
Mark
The 80th anniversary of von Willebrand's disease: history, management and research
(
- Contribution to journal › Scientific review
-
Mark
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum's disease.
2006) p.516-518(
- Chapter in Book/Report/Conference proceeding › Book chapter